about the only good thing I see here is that with the data being unblinded (and I agree that they had looked at the 210 and 500ish) maybe a 'partner' that they may be talking to can now discuss with the FDA an agreement on a fresh study / endpoints and hopefully that partner has the expertise to run a fairly quick trial under new endpoints, Basically they waited too long the trial fizzled with no push towards enrollment.
I agree with you - no sense pulling the trigger here - I'll just hold tight and see what the next 3 - 5 years bring.
When a company meets with the DSMB on a blinded trial the only folks that see the actual data is the DSMB. Revive did not see any of the 500 all they get is an over arching recommendation on where to go next. Officially unblinding the data will put all the raw data in Revive’s hands for the first time and stop the trial completely. This will allow them to package up whatever positive data they have in order to grab that partner or sell it outright. If they find positive symptoms reduction along with no hospitalizations or death; basically data that shows Bucillamine has promise it will put all investors in a position to make their money back. Don’t forget trials aren’t cheap! Revive’s current market cap is less than what they spent on the trial itself, crazy! Good luck!
News 
Market Data 
Discover 
